ibd: safety and positioning of il-23 inhibitors under investigation
Published 3 years ago • 2.1K plays • Length 12:15Download video MP4
Download video MP3
Similar videos
-
18:38
positioning anti-il-12 and anti-il-23 inhibitors
-
22:05
understanding the use of il12/il23 targeted biologics
-
22:00
novel jak inhibitors under investigation for ibd
-
20:09
targeting the il-12/23 pathway in ibd
-
30:34
advances in anti-cytokine therapy for ibd: the role of il-12/23 and il-23 inhibitors
-
12:48
ibd clinical update: new and emerging targeted therapies
-
15:09
novel targets and therapeutic perspectives in ibd: beyond anti-tnf
-
20:47
positioning inhibitors of lymphocyte trafficking
-
25:33
understanding the mechanisms of action of new agents: implications for efficacy and safety
-
18:23
selection and use of the new and coming therapies for ibd? who? when? how?
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
6:22
antibiotics and risk of new onset inflammatory bowel disease: a meta-analysis
-
23:55
new biologic therapies that target the il-12/23 pathway
-
12:58
positioning of biologics and new therapeutics for crohn's disease
-
18:03
understanding the contraindications to the use of immunomodulators and biologics for ibd
-
49:17
the evolving therapeutic paradigm in ibd: optimal positioning of new and emerging agents
-
8:25
vedolizumab as a treatment for crohn’s disease: efficacy and safety
-
21:13
update on vedolizumab in ibd: what have we learned?
-
20:57
leveraging jak inhibitors in ulcerative colitis: strategies for the ibd management team